2012-02-29 09:53 Cobra Biologics Cobra Biologics today announces that it has signed an agreement with a clinical stage biotechnology company to produce a Drug Substance under cGMP. The product, consisting of live bacteria, will be used for toxicology and clinical studies for treatment of a metabolic disorder. The disorder is a rare genetic disease leading to kidney failure and end stage renal disease.

2012-02-13 14:10 Cobra Biologics Cobra Biologics announces the appointment of three non-executive directors to Cobra Biologics’ board, and two business development managers tasked with driving continued growth in Europe and North America.The appointment of three non-executive directors, Elisabeth Lindner, Professor Carl Johan Sundberg and Jinyue Wang, further reinforces the business acumen across the Cobra Biologics’ board.

2011-10-31 14:19 Cobra Biologics Cobra Biologics is pleased to announce as part of its strategy to expand its service offering the acquisition of Unitech Pharma Group and its bio-production facility in Matfors near Sundsvall, Sweden.

2011-10-31 12:00 Cobra Biologics Cobra Biologics, internationell tillverkare av biologiska läkemedel, blir ny ägare till Unitech Pharma i Matfors genom förvärv av 100 procent av aktierna i bolaget.

2011-06-09 10:00 Cobra Biologics Unitech Pharma AB has entered a contract manufacturing agreement with the Uppsala-based company Immunsystem for the drug product manufacturing of Anti-Pseudomonas IgY. In a couple of months Immunsystem will start a phase III study for treatment of cystic fibrosis (CF) patients.

2011-01-20 15:28 APL AB

2011-01-12 13:25 Cobra Biologics Unitech Pharma AB today announced that the company has entered into a contract manufacturing agreement with Isofol Medical AB and Merck & Cie for the drug product manufacturing of the novel folate-based investigational drug product Modufolin®.

2010-06-08 16:21 Cobra Biologics Unitech Pharma AB announces today that it will provide Aprea AB with additional GMP manufacturing of APR-246. APR-246 is Aprea’s first candidate drug which is undergoing a Phase I clinical study for refractory hematological malignancies and prostate cancer patients in Sweden.

2010-06-07 15:17 Cobra Biologics We have noticed that many of our customers are looking for a partner that can handle the complete value chain, from process development to commercial production. To be able to meet that demand we have added a process development hub with experienced employees and top class facilities including a pilot plant asset.

2010-06-04 16:16 Cobra Biologics On February 1st Björn Sjöstrand started as the CEO of Unitech Pharma, the holding company of the contract manufacturing organization Unitech Biopharma, with Annette Elmqvist as CEO.